StockData
Acrivon Therapeutics, Inc. logo

Acrivon Therapeutics, Inc. (ACRV) stock

ACRVNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/30
$1.43−0.03 (-2.05%)

Close on Nov 17, 2026Market cap $61.28MP/E –Yield –

Acrivon Therapeutics enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Acrivon Therapeutics's enterprise value was -$22.69M on Nov 11, 2026, against -$54.80M a year earlier. Over the last 4 years it ranged from -$135.76M to $317.67M, with a median of -$22.69M.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026-$22.69M–
2025Dec 31, 2025-$53.22M–
2024Dec 31, 2024-$45.03K–
2023Dec 29, 2023-$33.34M–
2022Dec 30, 2022-$56.13M–

More Acrivon Therapeutics figures

See a number that looks wrong?